Condition: Prostate Cancers · Breast Cancer · Lung Cancers · Sponsor: Filamon LTD
This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II. Primary objective is to evaluate safety and tolerability of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers. Secondary objective is to characterise the pharmacokinetics of KESONOTIDE™. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.
This description comes directly from the study's public registry record.
Admir Huseincehajic · +61467451064 · admir.huseincehajic@filamon.com
Graham Kelly · +61 429 854 390 · graham.kelly@filamon.com
Always discuss trial participation with your own doctor first.
| St George Private Hospital | Kogarah, New South Wales, Australia | Recruiting |
| South Western Sydney Local Health District | Liverpool, New South Wales, Australia | Recruiting |
| Southside Cancer Centre | Miranda, New South Wales, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06926075